In this study, participants will receive either the medication Landiobloc, which contains landiolol hydrochloride, or a placebo. Landiolol hydrochloride is a type of medication known as a beta-blocker, which helps to slow down the heart rate and reduce the heart’s workload. The study will also use a solution called sodium chloride, commonly known as saline, which is often used in medical settings to provide fluids and electrolytes.

The purpose of the study is to determine if landiolol hydrochloride can effectively reduce the occurrence of LCOS after mitral valve surgery. Participants will be randomly assigned to receive either the medication or a placebo during their surgery. The study will monitor the participants’ heart function and recovery after surgery to assess the effects of the treatment. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, ensuring unbiased results.

The purpose of the study is to see if these medications can help reduce the risk of complications, shorten the length of hospital stay, and improve overall recovery after heart surgery. Participants will receive either the medication or a placebo, which looks like the medication but does not contain any active ingredients. The study will also look at different ways to manage blood flow and breathing during surgery to see if these methods can further improve recovery.

Throughout the study, participants will be monitored for up to 90 days after their surgery to track their recovery progress. The main focus will be on how many days they are alive and outside the hospital during this period. The study will also look at other important outcomes, such as survival rates, the occurrence of complications like stroke or kidney injury, and overall quality of life after surgery. This research aims to find the best ways to support patients’ recovery and improve their health outcomes after heart surgery.